Health Affairs October 12, 2023
As the COVID-19 pandemic unfolded in 2020, the Drug Enforcement Administration (DEA) ushered in groundbreaking telemedicine flexibilities pursuant to its public health emergency (PHE) authority under the Ryan Haight Act of 2008. These steps included allowing prescribing clinicians to initiate buprenorphine treatment for opioid use disorder (OUD) via telemedicine more easily. Previously, such an option was heavily restricted in the United States. These changes gave clinicians the flexibility to respond to the nation’s overdose crisis and increased patients’ access to and convenience in addiction care that have been associated with reduced odds of medically treated overdose, improved retention in care, and better adherence to treatment among veterans.
Then in March 2023, with joint notices of proposed rulemakings (NPRM) issued by...
Today's Sponsors
Today's Sponsor